ergoline and Syndrome

Topics: Clinical Trials as Topic; Deafness; Ergolines; Female; Humans; Infusions, Parenteral; Labyrinth Diseases; Male; Nicergoline; Syndrome; Tinnitus; Vertigo

Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT) syndrome may be associated with pituitary prolactinoma and may be induced by treatment of prolactinoma with dopamine agonists. Endocrinologists treating patients with prolactinoma need to be aware of this syndrome as its pathophysiology and treatment differ from that of other headache syndromes.

Topics: Adult; Cabergoline; Dopamine Agonists; Ergolines; Headache; Humans; Male; Prolactinoma; Syndrome

Topics: Animals; Dihydropyridines; Ergolines; Isradipine; Leydig Cell Tumor; Male; Pituitary Hormones; Rats; Rats, Inbred Strains; Syndrome; Testicular Hormones; Time Factors

A total of 122 male subjects suffering from secretory infertility were examined. In 25 of them (20 percent) blood prolactin levels were above the norm. Measurements of basal prolactin levels and of its secretion in metoclopramide test helped distinguish two types of hyperprolactinemia syndrome, differing in the pattern of spermatogenesis disorders. Possible pathogenesis of individual types of hyperprolactinemia in men is discussed. Therapy with dopamine agonists (lisenyl, parlodel) was found most effective in Type I hyperprolactinemia syndrome, associated with essential prolactin hypersecretion and oligospermia.

Topics: Adult; Bromocriptine; Ergolines; Humans; Hyperprolactinemia; Infertility, Male; Lisuride; Male; Middle Aged; Oligospermia; Prolactin; Syndrome

Lysenyl-forte, a derivative of polysynthetic ergot alkaloids, producing a dopaminergic and antiserotoninergic action was employed to treat acromegaly and prolactin hypersecretion in 11 and 71 patients, respectively. Clinical effect was established basing on a complex of clinical, x-ray, neuro-ophthalmologic and hormonal evidence. Acromegaly treatment proved efficient: 7 patients (63%) showed partial relief of clinical signs, reduced STH blood level. Out of 48 patients with prolactinemia a response was registered in 34 (71%): a more than 50% decrease in prolactin concentration, normal levels of the hormone in 35% of the patients. A menstrual cycle recovered, galactorrhea diminished, 2 women got pregnant. A positive effect was noticed in management of 13 sterile men with prolactin hypersecretion, in 6 patients with idiopathic prolactin hypersecretion, in 4 women with primary hypothyrosis and galactorrhea. Compared to parlodel, lysenyl was not superior in the frequency of side effects, though was inferior in clinical effectiveness. The drug is recommended for wide-scale use.

Topics: Acromegaly; Adolescent; Adult; Aged; Aged, 80 and over; Bromocriptine; Drug Evaluation; Ergolines; Female; Humans; Hyperprolactinemia; Lisuride; Male; Middle Aged; Syndrome

The ergolene derivative MPME (PTR 17402; (5R,8R)-8-(4-p-methoxyphenyl)-1-piperazynylmethyl-6- methylergolene], a dopamine (DA) receptor agonist acting mainly at DA D-1 receptors linked to dotted types of forebrain DA nerve terminals, induces a characteristic behavioural syndrome consisting of increased locomotion, head-bobbing and sniffing activity without oral stereotypies or increased rearing. Haloperidol and cis-flupenthixol, nonselective DA receptor antagonists, but not selective D-2 receptor antagonists such as remoxipride and sulpiride, could significantly counteract the locomotion and head-bobbing behaviour induced by MPME. In contrast, the sniffing behaviour induced by MPME was only marginally affected by haloperidol and cis-flupenthixol pretreatment. These results suggest that activation of D-1 receptors in the forebrain mainly linked to the dotted types of DA nerve terminals in the striatum, and in the limbic forebrain, can result in behavioural effects which differ from those caused by stimulation of D-2 receptors located mainly within the diffuse types of DA nerve terminal systems.

Topics: Animals; Antipsychotic Agents; Apomorphine; Diencephalon; Ergolines; Humans; Male; Motor Activity; Nerve Endings; Piperidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Stereotyped Behavior; Syndrome; Telencephalon

Topics: Animals; Basal Ganglia Diseases; Chorea; Corpus Striatum; Dystonia; Ergolines; Female; Humans; Lisuride; Male; Middle Aged; Parkinson Disease; Rats; Syndrome; Torticollis

10 amenorrhea-patients and 5 galactorrhea-amenorrhea-patients were treated wi2-Br-alpha-ergocryptine (CB 154) as a specific prolactin inhibitor. Side-effects, such as headaches, dizziness, and nausea could be reduced to a minimum by delivering the drug with the meal at night. Before and under the treatment hormone levels were determined in plasma and 24-hour-urine. In the beginning all 15 patients showed a hyperprolactinaemia with a nearly always simultaneously existing hypogonadotropinaemia and the absence of LH-peaks. Also the estrogen- and progesterone-concentrations were on the lower normal level or extremely suppressed. In all patients CB 154 therapy led to a quick decrease of the prolactin levels, to a regaining of typical LH- and FSH-episodes, as well as to a regeneration of ovarian function. 5 women reacted with an ovulation, 3 became pregnant. The galactorrhea diminished significantly and stopped finally after a treatment of one week to 6 months. Discontinuation of CB 154-therapy, however, often provoked the galactorrhea-amenorrhea-syndrome again. For women with normoprolactinaemic amenorrhea a gestagen- and estrogen-test were carried out in order to classify the amenorrhea-type and it was tried to induce an ovulation with Dyneric. For patients with a strong desire for children and without any organic cause for their sterility, in cases of ovarian insufficiency grade I and II a HMG-HCG-treatment was often indicated. In spite of a precise control in order to avoid an overstimulation of the ovaries about 1% of the Dyneric-treated and even 30% of the HMG-HCG-treated patients developed ovarian cysts. In spite of high doses of gonadotropins only 32,5% of our sterility-patients (group I and II) became pregnant, whereas about 60% of the hyperprolactinaemic amenorrhea-patients (group VI) conceived under CB 154 treatment.

Topics: Adult; Amenorrhea; Ergolines; Female; Galactorrhea; Gonadotropins; Humans; Lactation Disorders; Luteinizing Hormone; Ovulation; Pregnancy; Prolactin; Syndrome

Eleven women with secondary amenorrhoea and hyperprolactinaemia were treated with lisuride, a new semisynthetic ergot derivative. Acute administration of lisuride (100 microgram orally) significantly suppressed serum prolactin (PRL) levels in nine out of eleven subjects. In these nine patients, prolonged treatment with lisuride (50--200 microgram daily) lowered PRL levels into the normal range, menstrual cycles were resumed and eight patients ovulated. Two patients, in whom lisuride failed to lower PRL levels into the normal range, did not resume normal menstruation. These data demonstrate that lisuride may be used clinically to lower PRL levels and to restore cyclic gonadotrophin secretion and ovulation in amenorrhoeic patients with hyperprolactinaemia.

Topics: Adult; Amenorrhea; Ergolines; Female; Galactorrhea; Humans; Lisuride; Ovulation; Pregnancy; Prolactin; Syndrome; Thyrotropin-Releasing Hormone

Topics: Anaphylaxis; Bromocriptine; Ergolines; Female; Humans; Middle Aged; Syndrome

A patient is described with a galactorrhea-amenorrhea syndrome and an enlargement of the sella turcica. Pregnancy occurred after induction of ovulation with bromocriptine (and 2.5 years after pituitary irradiation). Periodic assessment of the visual fields showed an increase in size of the blind spots after 10 weeks and a moderate bitemporal hemianopsia after 22 weeks, which improved spontaneously after 30 weeks of pregnancy. One month after delivery the visual field of the left eye was almost normalized, while that of the right eye showed a definite improvement. Prior radiotherapy need not prevent visual complications from enlargement of pituitary adenomas during pregnancy.

Topics: Adult; Amenorrhea; Bromocriptine; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Galactorrhea; Hemianopsia; Humans; Lactation Disorders; Luteinizing Hormone; Pituitary Neoplasms; Pregnancy; Pregnancy Complications; Prolactin; Syndrome; Visual Fields

Prolactin interferes with the function of the corpus luteum, as was demonstrated by repeatedly finding a short luteal phase in the ovulatory cycles of two hyperprolactinaemic women after prolactin supression by bromocriptine had been discontinued. In hyperprolactinaemic ovulatory cycles excretion of pregnanediol in urine was less and plasma-progesterone concentrations were lower than in normo-prolactinaemic cycles. When the amenorrhoea-galactorrhoea syndrome recurred the symptoms appeared in the following order: (1) serum-prolactin increased and the luteal phase became shorter; (2) galactorrhoea appeared; (3) ovulation was missed; (4) menstruation was missed. All these abnormalities may be treated by prolactin suppression, but the effect of treatment does not persist for long after bromocriptine administration ceases.

Topics: Adult; Amenorrhea; Bromocriptine; Ergolines; Female; Galactorrhea; Humans; Luteal Phase; Menstruation; Ovulation; Pregnancy; Prolactin; Syndrome; Time Factors

Topics: Adrenalectomy; Adrenocorticotropic Hormone; Adult; Bromocriptine; Cushing Syndrome; Ergolines; Female; Humans; Male; Postoperative Complications; Prolactin; Syndrome

Fifteen patients with galactorrhea-amenorrhea syndromes were studied before, during, and after treatment with bromergocryptine. Galactorrhea and amenorrhea were noted after pregnancy (6 patients), after oral contraceptive therapy (5 patients), and in association with pituitary adenoma (4 patients). Before treatment prolactin values were elevated ranging from 27 to 125 ng/ml, while luteinizing hormone and progesterone levels failed to show ovulatory peaks or luteal phase progression. Eleven patients had luteinizing hormone-releasing hormone tests before therapy. Response was normal in 8, subnormal in 2 pituitary adenoma, and supranormal in 1 patient with premature ovarian failure. Treatment with bromergocryptine was associated with a lowering of serum prolactin, cessation of lactation in all, and return of ovulatory menses in 14 of 15 patients. All relapsed when therapy was discontinued. Four patients became pregnant while on therapy. Long-term bromergocryptine therapy is effective for all forms of galactorrhea-amenorrhea syndromes studied.

Topics: Adenoma; Amenorrhea; Bromocriptine; Chiari-Frommel Syndrome; Ergolines; Female; Galactorrhea; Humans; Lactation Disorders; Pituitary Function Tests; Pituitary Neoplasms; Pregnancy; Recurrence; Syndrome

A woman developed amenorrhoea and galactorrhoea after partial removal of a pituitary tumor during pregnancy. Hyperprolactinaemia was supressed by therapy with bromocryptine (CB 154, Sandoz) resulting in cessation of galactorrhoea in two months, spontaneous menstruation after eight months, and pregnancy after twelve months.

Topics: Adenoma, Chromophobe; Adult; Amenorrhea; Bromocriptine; Ergolines; Female; Galactorrhea; Humans; Lactation Disorders; Pituitary Neoplasms; Pregnancy; Syndrome

Topics: Amenorrhea; Brain; Bromocriptine; Depression, Chemical; Dopamine; Ergolines; Female; Galactorrhea; Humans; Lactation Disorders; Male; Pregnancy; Prolactin; Receptors, Drug; Syndrome

2 Bromo-alpha-ergocryptine, a specific prolactin inhibitor, was administered to 9 patients suffering from galactorrhea-amenorrhea syndrome of varying aetiology. Plasma levels of FSH, LH, prolactin, total estrogens and progesterone were measured by radioimmunoassy before and after treatment initiation. Prior to treatment, plasma prolactin levels were in all cases supraphysiological. FSH and LH levels were, with the exception of one patient, in the low cyclic range. One patient had subnormal gonadotropin levels, presumably reflecting hypophyseal insufficiency following surgical removal of a pituitary adenoma. Mean plasma levels of total estrogens were in the lower normal range. Administration of CB 154 led in all cases to a reduction of plasma prolactin levels. In eight cases, galactorrhea was suppressed during the first month of treatment. Eight patients menstruated and seven ovulated as indicated by the basal body temperature (BBT) or plasma progesterone measurement. The postoperative hypophyseal tumor patient did not, with the exception of galactorrhea suppression, respond to treatment, presumably due to hypophyseal insufficiency. 2 patients conceived during the course of treatment. One patient, who developed galactorrhea-amenorrhea syndrome as a result of psychopharmacological drug administration received 7,5 mg/day CB 154. Prolactin secretion, as indicated by plasma levels, was inhibited but the inhibitation was much slower in onset than that exhibited by the other patients and this patient ovulated only after 5 months of treatment. Upon withdrawal of CB 154 therapy after 6 to 7 months, the patients redeveloped galactorrhea-amenorrhea syndrome, so that a definitive cure could not be demonstrated.

Topics: Adult; Amenorrhea; Bromocriptine; Contraceptives, Oral; Ergolines; Estrogens; Female; Follicle Stimulating Hormone; Galactorrhea; Humans; Hypophysectomy; Lactation Disorders; Luteinizing Hormone; Pregnancy; Progesterone; Prolactin; Psychotropic Drugs; Radioimmunoassay; Syndrome

Recent progress in the field of radioimmunology, especially as regards prolactin (PRL) assay, as well as the use of new drugs have opened new perspectives for a better understanding of the "amenorrhoea-galactorrhea syndrome" both from the diagnostic and therapeutic points of view. This syndrome which formerly was considered infrequent, is now observed more and more often, perhaps as a result of the more widespread use of drugs such as phenothiazines, reserpine derivatives, alpha-methyldopa and tricyclic antidepressants, as well as owing to the large-scale use of estrogens and above all of estrogen-progestogen contraceptives. The problems of etiopathogenesis and management of the amenorrhea-galactorrhea syndrome are complicated by the fact that a variety of factors are responsible, as is shown also by the classical nosographic classification with the Forbes-Albright syndrome in the presence of a pituitary tumour, the Chiari-Frommel syndrome of amenorrhea-galactorrhea following pregnancy, and the Argonz-del Castillo-Ahumada syndrome in the absence of lither pregnancy or tumor.

Topics: Adult; Amenorrhea; Ergolines; Estradiol; Female; Follicle Stimulating Hormone; Galactorrhea; Humans; Lactation Disorders; Luteinizing Hormone; Pituitary Hormone Release Inhibiting Hormones; Pregnancy; Progesterone; Prolactin; Radioimmunoassay; Syndrome

Topics: Aged; Amnesia; Brain; Ergolines; Humans; Male; Memory Disorders; Memory, Short-Term; Syndrome